Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Uchuya-Castillo J, Aznar N, Frau C, Martinez P, Le Nevé C, Marisa L, Penalva LOF, Laurent-Puig P, Puisieux A, Scoazec JY, Samarut J, Ansieau S, Plateroti M.

Oncotarget. 2018 Jul 24;9(57):30979-30996. doi: 10.18632/oncotarget.25741. eCollection 2018 Jul 24.

2.

Destabilization of the TWIST1/E12 complex dimerization following the R154P point-mutation of TWIST1: an in silico approach.

Bouard C, Terreux R, Tissier A, Jacqueroud L, Vigneron A, Ansieau S, Puisieux A, Payen L.

BMC Struct Biol. 2017 May 18;17(1):6. doi: 10.1186/s12900-017-0076-x.

3.

A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.

Morel AP, Ginestier C, Pommier RM, Cabaud O, Ruiz E, Wicinski J, Devouassoux-Shisheboran M, Combaret V, Finetti P, Chassot C, Pinatel C, Fauvet F, Saintigny P, Thomas E, Moyret-Lalle C, Lachuer J, Despras E, Jauffret JL, Bertucci F, Guitton J, Wierinckx A, Wang Q, Radosevic-Robin N, Penault-Llorca F, Cox DG, Hollande F, Ansieau S, Caramel J, Birnbaum D, Vigneron AM, Tissier A, Charafe-Jauffret E, Puisieux A.

Nat Med. 2017 May;23(5):568-578. doi: 10.1038/nm.4323. Epub 2017 Apr 10.

PMID:
28394329
4.

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J.

EMBO Mol Med. 2016 Oct 4;8(10):1143-1161. doi: 10.15252/emmm.201505971. Print 2016 Oct.

5.

The Heterodimeric TWIST1-E12 Complex Drives the Oncogenic Potential of TWIST1 in Human Mammary Epithelial Cells.

Jacqueroud L, Bouard C, Richard G, Payen L, Devouassoux-Shisheboran M, Spicer DB, Caramel J, Collin G, Puisieux A, Tissier A, Ansieau S.

Neoplasia. 2016 May;18(5):317-327. doi: 10.1016/j.neo.2016.03.007.

6.

Deciphering the molecular mechanisms underlying the binding of the TWIST1/E12 complex to regulatory E-box sequences.

Bouard C, Terreux R, Honorat M, Manship B, Ansieau S, Vigneron AM, Puisieux A, Payen L.

Nucleic Acids Res. 2016 Jun 20;44(11):5470-89. doi: 10.1093/nar/gkw334. Epub 2016 May 5.

7.

TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability.

Pommier RM, Gout J, Vincent DF, Alcaraz LB, Chuvin N, Arfi V, Martel S, Kaniewski B, Devailly G, Fourel G, Bernard P, Moyret-Lalle C, Ansieau S, Puisieux A, Valcourt U, Sentis S, Bartholin L.

Cancer Res. 2015 Oct 15;75(20):4335-50. doi: 10.1158/0008-5472.CAN-14-3426. Epub 2015 Aug 17.

8.

Senescence versus apoptosis in chemotherapy.

Ansieau S, Collin G.

Oncotarget. 2015 Mar 10;6(7):4551-2. No abstract available.

9.

EMT or EMT-Promoting Transcription Factors, Where to Focus the Light?

Ansieau S, Collin G, Hill L.

Front Oncol. 2014 Dec 16;4:353. doi: 10.3389/fonc.2014.00353. eCollection 2014. Review. No abstract available.

10.

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F, Ansieau S.

Mol Cancer. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213.

11.

Snail family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammary epithelial cells.

Gras B, Jacqueroud L, Wierinckx A, Lamblot C, Fauvet F, Lachuer J, Puisieux A, Ansieau S.

PLoS One. 2014 Mar 17;9(3):e92254. doi: 10.1371/journal.pone.0092254. eCollection 2014.

12.

TWIST1 expression in breast cancer cells facilitates bone metastasis formation.

Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A, Clézardin P.

J Bone Miner Res. 2014 Aug;29(8):1886-99. doi: 10.1002/jbmr.2215.

13.

Plasticity of melanoma and EMT-TF reprogramming.

Tulchinsky E, Pringle JH, Caramel J, Ansieau S.

Oncotarget. 2014 Jan 15;5(1):1-2. No abstract available.

14.

A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E.

Cancer Cell. 2013 Oct 14;24(4):466-80. doi: 10.1016/j.ccr.2013.08.018. Epub 2013 Sep 26.

15.

Modulation of oxidative stress by twist oncoproteins.

Floc'h N, Kolodziejski J, Akkari L, Simonin Y, Ansieau S, Puisieux A, Hibner U, Lassus P.

PLoS One. 2013 Aug 13;8(8):e72490. doi: 10.1371/journal.pone.0072490. eCollection 2013.

16.

Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes.

Bouard C, Terreux R, Hope J, Chemelle JA, Puisieux A, Ansieau S, Payen L.

J Biomol Struct Dyn. 2014;32(2):226-41. doi: 10.1080/07391102.2012.762722. Epub 2013 Mar 25.

17.

Structural and functional analysis of the DEAF-1 and BS69 MYND domains.

Kateb F, Perrin H, Tripsianes K, Zou P, Spadaccini R, Bottomley M, Franzmann TM, Buchner J, Ansieau S, Sattler M.

PLoS One. 2013;8(1):e54715. doi: 10.1371/journal.pone.0054715. Epub 2013 Jan 25.

18.

EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.

Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S, Puisieux A.

PLoS Genet. 2012;8(5):e1002723. doi: 10.1371/journal.pgen.1002723. Epub 2012 May 24.

19.

EMT in breast cancer stem cell generation.

Ansieau S.

Cancer Lett. 2013 Sep 10;338(1):63-8. doi: 10.1016/j.canlet.2012.05.014. Epub 2012 May 22. Review.

PMID:
22634497
20.

TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma.

Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M, Ansieau S, Puisieux A, Laurent-Puig P, Blons H.

PLoS One. 2012;7(1):e29954. doi: 10.1371/journal.pone.0029954. Epub 2012 Jan 17.

21.

Failsafe program escape and EMT: a deleterious partnership.

Ansieau S, Courtois-Cox S, Morel AP, Puisieux A.

Semin Cancer Biol. 2011 Dec;21(6):392-6. doi: 10.1016/j.semcancer.2011.09.014. Epub 2011 Oct 5. Review.

PMID:
21986518
22.

TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression.

Ruptier C, De Gaspéris A, Ansieau S, Granjon A, Tanière P, Lafosse I, Shi H, Petitjean A, Taranchon-Clermont E, Tribollet V, Voeltzel T, Scoazec JY, Maguer-Satta V, Puisieux A, Hainaut P, Cavard C, Caron de Fromentel C.

Oncogene. 2011 Nov 17;30(46):4656-65. doi: 10.1038/onc.2011.171. Epub 2011 Jun 6.

PMID:
21643019
23.

[An alternate model of tumoral progression].

Ansieau S, Puisieux A.

Biol Aujourdhui. 2011;205(1):47-52. doi: 10.1051/jbio/2011001. Epub 2011 Apr 19. Review. French.

PMID:
21501575
24.

TWISTing an embryonic transcription factor into an oncoprotein.

Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A.

Oncogene. 2010 Jun 3;29(22):3173-84. doi: 10.1038/onc.2010.92. Epub 2010 Apr 12. Review.

PMID:
20383196
25.

Revisiting the canonical tumour progression model.

Ansieau S, Hinkal G, Morel AP, Puisieux A.

Pathol Biol (Paris). 2011 Dec;59(6):294-7. doi: 10.1016/j.patbio.2009.11.005. Epub 2010 Mar 15. Review. No abstract available.

PMID:
20227838
26.

The SNAIL family member SCRATCH1 is not expressed in human tumors.

Bastid J, Bouchet BP, Ciancia C, Pourchet J, Audoynaud C, Grelier G, Puisieux A, Ansieau S.

Oncol Rep. 2010 Feb;23(2):523-9.

PMID:
20043117
27.

[Role of the epithelial-mesenchymal transition during tumor progression].

Ansieau S, Caron de Fromentel C, Bastid J, Morel AP, Puisieux A.

Bull Cancer. 2010 Jan;97(1):7-15. doi: 10.1684/bdc.2009.1025. French.

28.

Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Bérard N.

Nat Immunol. 2009 Jul;10(7):778-85. doi: 10.1038/ni.1741. Epub 2009 May 31. Retraction in: Nat Immunol. 2014 Sep;15(9):894.

PMID:
19483719
29.

[The premature senescence: chimera, saving angel or Dr Jekyll and Mr Hyde?].

Puisieux A, Ansieau S.

Med Sci (Paris). 2009 Feb;25(2):115-6. doi: 10.1051/medsci/2009252115. French. No abstract available.

30.

[The key implication of early migration of metastatic cells].

Puisieux A, Ansieau S.

Med Sci (Paris). 2009 Jan;25(1):28-9. doi: 10.1051/medsci/200925128. French. No abstract available.

31.

Early origin of cancer metastases: dissemination and evolution of premalignant cells.

Ansieau S, Hinkal G, Thomas C, Bastid J, Puisieux A.

Cell Cycle. 2008 Dec;7(23):3659-63. Epub 2008 Dec 19. Review.

PMID:
19029812
32.

Generation of breast cancer stem cells through epithelial-mesenchymal transition.

Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A.

PLoS One. 2008 Aug 6;3(8):e2888. doi: 10.1371/journal.pone.0002888.

33.

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A.

Cancer Cell. 2008 Jul 8;14(1):79-89. doi: 10.1016/j.ccr.2008.06.005.

34.

Retraction notice to "Structure and functional analysis of the MYND domain" [J. Mol. Biol. (2006) 358, 498-508].

Spadaccini R, Perrin H, Bottomley MJ, Ansieau S, Sattler M.

J Mol Biol. 2008 Mar 7;376(5):1523. No abstract available.

PMID:
18286714
35.

[microRNA in cancer, small but risky].

Puisieux A, Ansieau S.

Med Sci (Paris). 2008 Feb;24(2):135-6. doi: 10.1051/medsci/2008242135. French. No abstract available.

36.

Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation?

Bastid J, Puisieux A, Ansieau S.

Clin Med Oncol. 2008;2:363-6. Epub 2008 Apr 29.

37.

New insights into BS69 functions.

Velasco G, Grkovic S, Ansieau S.

J Biol Chem. 2006 Jun 16;281(24):16546-50. Epub 2006 Mar 24.

38.

Structure and functional analysis of the MYND domain.

Spadaccini R, Perrin H, Bottomley MJ, Ansieau S, Sattler M.

J Mol Biol. 2006 Apr 28;358(2):498-508. Epub 2006 Feb 8. Retraction in: Spadaccini R, Perrin H, Bottomley MJ, Ansieau S, Sattler M. J Mol Biol. 2008 Mar 7;376(5):1523.

PMID:
16527309
39.

A twist for survival and cancer progression.

Puisieux A, Valsesia-Wittmann S, Ansieau S.

Br J Cancer. 2006 Jan 16;94(1):13-7. Review.

40.

[BS69 and RACK7, a potential novel class of tumor suppressor genes].

Ansieau S, Sergeant A.

Pathol Biol (Paris). 2003 Sep;51(7):397-9. French. No abstract available.

PMID:
12948759
41.

The LIM domain protein Lmo2 binds to AF6, a translocation partner of the MLL oncogene.

Bégay-Müller V, Ansieau S, Leutz A.

FEBS Lett. 2002 Jun 19;521(1-3):36-8.

42.

The conserved Mynd domain of BS69 binds cellular and oncoviral proteins through a common PXLXP motif.

Ansieau S, Leutz A.

J Biol Chem. 2002 Feb 15;277(7):4906-10. Epub 2001 Dec 3.

43.
44.

The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.

Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A.

Oncogene. 1999 Jun 3;18(22):3316-23.

45.

B-Myb, a repressed trans-activating protein.

Ansieau S, Kowenz-Leutz E, Dechend R, Leutz A.

J Mol Med (Berl). 1997 Nov-Dec;75(11-12):815-9.

PMID:
9428611
46.

Cloning of two novel human importin-alpha subunits and analysis of the expression pattern of the importin-alpha protein family.

Köhler M, Ansieau S, Prehn S, Leutz A, Haller H, Hartmann E.

FEBS Lett. 1997 Nov 3;417(1):104-8.

47.

Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.

Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM, Leprince D.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7.

48.

Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.

Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss HJ.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14053-8. Retraction in: Kieff E. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12732.

49.

Regulation of C/EBP beta/NF-M activity by kinase oncogenes.

Twamley-Stein G, Kowenz-Leutz E, Ansieau S, Leutz A.

Curr Top Microbiol Immunol. 1996;211:129-36.

PMID:
8585943
50.

The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.

Dhordain P, Albagli O, Ansieau S, Koken MH, Deweindt C, Quief S, Lantoine D, Leutz A, Kerckaert JP, Leprince D.

Oncogene. 1995 Dec 21;11(12):2689-97.

PMID:
8545127

Supplemental Content

Loading ...
Support Center